## Tumor Volume and T2 Hyperintensity Changes from DeFi: A Phase 3, Randomized, Controlled Trial of Nirogacestat in Patients With Desmoid Tumors

Thierry Alcindor,<sup>1\*</sup> Bernd Kasper,<sup>2</sup> Mrinal Gounder,<sup>3</sup> Ravin Ratan,<sup>4</sup> Winette T. van der Graaf,<sup>5</sup> Breelyn A. Wilky,<sup>6</sup> Richard F. Riedel,<sup>7</sup> Noah Federman,<sup>8,9</sup> Agnese Peruzzi,<sup>10</sup> Stephanie Moody,<sup>11</sup> Allison Lim,<sup>12</sup> Brad Tumminello,<sup>12</sup> Sandra Goble,<sup>12</sup> Shivaani Kummar,<sup>13</sup> Patrick Schöffski<sup>14</sup>

<sup>1</sup>Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada; <sup>2</sup>University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit, Mannheim, Germany; <sup>3</sup>Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA; <sup>4</sup>Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>5</sup>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; <sup>6</sup>University of Colorado Anschutz Medical Campus, Aurora, CO, USA; <sup>7</sup>Duke Cancer Institute, Durham, NC, USA; <sup>8</sup>David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; <sup>9</sup>UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; <sup>10</sup>Medpace, Cincinnati, OH, USA; <sup>11</sup>PharPoint Research, Durham, NC, USA; <sup>12</sup>SpringWorks Therapeutics, Stamford, CT, USA; <sup>13</sup>Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR, USA; <sup>14</sup>Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

\*Presenting author email: thierry\_alcindor@dfci.harvard.edu. Dr Alcindor is currently affiliated with Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA



## Supplemental Figure 1. Box-and-whisker plot of percent change in MRI-assessed tumor volume over time of the largest tumor (intent-to-treat population)

Supplemental Figure 2. Box-and-whisker plot of percent change in T2 hyperintensity signal ratio over time of the largest tumor (intent-to-treat population)



Where available, data are shown as the minimum (lower whisker), 25% percentile (lower bound of the box), 50% percentile (middle line in the box), 75% percentile (upper bound of the box), and maximum (upper whisker) values.

Scan QR code to access the poster content for Abstract 11514

